These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 22304225

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer.
    Xie Q, Chen H, Ai J, Gao YL, Geng MY, Ding J, Chen Y.
    Acta Pharmacol Sin; 2017 Nov; 38(11):1533-1542. PubMed ID: 28795691
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
    Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L.
    Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry.
    Yang Q, Li Q, Fan H.
    Arch Dermatol Res; 2024 Jul 03; 316(7):447. PubMed ID: 38958761
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.
    Sun Q, Zhou J, Zhang Z, Guo M, Liang J, Zhou F, Long J, Zhang W, Yin F, Cai H, Yang H, Zhang W, Gu Y, Ni L, Sai Y, Cui Y, Zhang M, Hong M, Sun J, Yang Z, Qing W, Su W, Ren Y.
    Cancer Biol Ther; 2014 Jul 03; 15(12):1635-45. PubMed ID: 25482937
    [Abstract] [Full Text] [Related]

  • 15. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
    LaMontagne KR, Butler J, Borowski VB, Fuentes-Pesquera AR, Blevitt JM, Huang S, Li R, Connolly PJ, Greenberger LM.
    Angiogenesis; 2009 Jul 03; 12(3):287-96. PubMed ID: 19544081
    [Abstract] [Full Text] [Related]

  • 16. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
    Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isae T.
    Cancer Res; 2006 Sep 15; 66(18):9134-42. PubMed ID: 16982756
    [Abstract] [Full Text] [Related]

  • 17. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY, Xu H, Wu ZF, Chen C, Liu JY, Wu GN, Yao XQ, Liu FK, Li G, Shen L.
    Oncotarget; 2015 Dec 29; 6(42):44563-78. PubMed ID: 26575424
    [Abstract] [Full Text] [Related]

  • 18. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
    Fan Y, Peng A, He S, Shao X, Nie C, Chen L.
    J Chemother; 2013 Oct 29; 25(5):298-308. PubMed ID: 24070138
    [Abstract] [Full Text] [Related]

  • 19. ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling.
    Su M, Huang J, Li J, Qin X, Tang X, Jin F, Chen S, Jiang C, Zou Z, Peng K, Nuruzzaman M, Zhang J, Luo J, Liu S, Luo Z.
    Oncotarget; 2016 Apr 05; 7(14):19018-30. PubMed ID: 26967559
    [Abstract] [Full Text] [Related]

  • 20. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro.
    Guo XB, Chen XJ, Tong LJ, Peng X, Huang M, Liu HC, Liu H, Ding J.
    Acta Pharmacol Sin; 2015 Oct 05; 36(10):1266-76. PubMed ID: 26027659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.